454 Life Sciences

454 Life Sciences was a U.S. life-science company focused on next-generation sequencing technologies, instruments, and reagents. It became known for commercializing massively parallel sequencing based on pyrosequencing-related methods, with applications in genome sequencing, transcriptomics, microbiology, and other molecular-biology research. Roche acquired the company and operated its sequencing activities within the Roche group for a period. Its best-known platforms included the GS FLX and GS Junior systems. As competition in sequencing intensified and the market shifted toward other technology architectures, Roche discontinued the 454 sequencing business, and 454 Life Sciences ceased operating as an independent active brand.

454 Life Sciences was established in the early 2000s with the aim of commercializing massively parallel sequencing for research laboratories. The company developed an early next-generation sequencing product line and sought to balance throughput, run time, and application breadth. Its systems were used in research involving genomes, transcriptomes, microorganisms, and targeted sequencing. Roche acquired 454 Life Sciences in 2007, after which the company became part of Roche's sequencing operations. Although the technology had an important place in the early next-generation sequencing market, competition increasingly favored alternative architectures offering higher throughput and lower cost per base. Roche announced the discontinuation of its 454 sequencing business in 2016, and the associated platforms and brand ceased to operate as an active major product line.

• 2016

  Discontinuation of 454 Sequencing Business

  Roche discontinued the 454 sequencing platform business, and the 454 brand ceased to operate as an active independent sequencing business.

• 2007

  Acquired by Roche

  Roche acquired 454 Life Sciences, obtaining its sequencing technology and related business.

• 2000

  Company Founded

  454 Life Sciences was founded, beginning development of massively parallel sequencing technology for life science research.

Next-generation sequencing platforms and solutions for research institutions, genomics laboratories, and life science researchers

• Next-generation sequencing instrument

  GS FLX

  GS FLX was a flagship next-generation sequencing platform from 454 Life Sciences for genomics, microbiology, and other life-science research, using dedicated sequencing reagents and analysis workflows.

• Benchtop next-generation sequencing instrument

  GS Junior

  GS Junior was a laboratory-scale 454 sequencing platform intended for smaller genome, amplicon, and targeted-sequencing projects, providing a more accessible format for research laboratories.

• 2016

  Discontinuation of 454 Sequencing Platform BusinessStrategy

  Background

  Competition in the sequencing market intensified, with other technology routes gaining advantages in throughput and per-unit cost.

  Action taken

  Roche discontinued the 454 sequencing business and continued operation of the related platform.

  Aftermath

  454 Life Sciences ceased to operate as a major active sequencing brand.

• 2016

  Roche discontinues 454 sequencing business

  Other

  罗氏宣布停止与454测序平台相关的业务，品牌随后不再作为活跃的独立测序业务运营。

• 2007

  Roche acquires 454 Life Sciences

  M&A

  罗氏收购454 Life Sciences，使其获得相关大规模并行测序技术和业务。